A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone

Trial Profile

A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Trifluridine
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 23 Jan 2017 Results published in the Investigational New Drugs.
    • 21 Dec 2015 Planned End Date changed from 1 Apr 2014 to 1 May 2016 as per ClinicalTrials.gov record.
    • 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top